Pricing Log in Create free account

Inventiva S.A. Sponsored ADR (IVA) vs Rigel Pharmaceuticals, Inc. (RIGL)

Inventiva S.A. Sponsored ADR and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Inventiva S.A. Sponsored ADR and Rigel Pharmaceuticals, Inc. are of similar size ($867.9M and $853.9M). Inventiva S.A. Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.4×. Inventiva S.A. Sponsored ADR grew revenue faster over the last twelve months: 547.9% against 2.18%. Rigel Pharmaceuticals, Inc. has the higher net margin (106.6% vs −750.3%) and the higher return on invested capital (13.7% vs 0.00%). Across the 18 metrics below, Rigel Pharmaceuticals, Inc. leads on 15 and Inventiva S.A. Sponsored ADR on 3.

Valuation

Metric IVA RIGL Biotechnology median
P/E n/m 2.35 10.60
P/S 7.43 2.57 9.40
P/B 2.13 1.66 2.13
Price to free cash flow n/m 37.96 25.18
EV/EBITDA n/m 8.30 0.66
EV/Sales 1.54 2.28 9.02
Earnings yield (94.51%) 42.49% (32.88%)
Free cash flow yield (94.32%) 2.63% (23.13%)

Profitability

Metric IVA RIGL Biotechnology median
Gross margin 0.00% 89.64% 68.51%
Operating margin 0.00% 26.28% 0.00%
Net margin (750.28%) 106.59% 0.00%
Free cash flow margin 0.00% 31.20% 0.00%
Return on equity 0.00% 109.18% (51.96%)
Return on assets 0.00% 80.16% (46.06%)
Return on invested capital 0.00% 13.69% 0.00%

Growth

Metric IVA RIGL Biotechnology median
Revenue growth (TTM) 547.89% 2.18% 6.76%
EPS growth (last fiscal year) 35.44% 1,867.68% 29.88%
Revenue growth, 5-year CAGR 8.33% 22.06% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IVA RIGL Biotechnology median
Debt to equity 1.13 0.00 0.00
Current ratio 3.81 2.39 4.97
Net debt to EBITDA 0.29 (1.05) 1.01

Dividend

Metric IVA RIGL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IVA RIGL Biotechnology median
Market cap 867.93m 853.86m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack